Neoadjuvant–adjuvant or adjuvant-only pembrolizumab in advanced melanoma.
Patel SP, Othus M, Chen Y, Wright GP, Yost KJ, Hyngstrom JR et al.
N Engl J Med 2023; 388: 813-823.
Some 313 patients with advanced melanoma undergoing surgical resection followed by one year of adjuvant Pembrolizumab, were randomly allocated three additional doses of Pembrolizumab preoperatively. After two years, event-free survival was significantly better with the neoadjuvant treatment: 72 versus 49 per cent, P=0.004.
Comment: This is important evidence for the benefit of neoadjuvant treatment for melanoma.
26 April 2023Read paper
Part of the charitable activity of the Society, BJS Academy is an online educational resource for current and future surgeons.
The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.